2025 Poster Presentations Coming in August

Here is a reminder of the 2024 Posters

A01: Production of AAV Vectors Using Synthetic, Enzymatically Produced Linear DNA, Presented by Florent F., 4basebio Discovery Ltd.

A02: Data-Driven Feed Strategy Optimisation and Scale-Up of mAb-Expressing CHO Cell Line Bioprocess, Presented by Tessel H., 908 Devices, Inc.

A03: In-Depth Metabolic Characterization at Different Phases of Cell Culture with a Turnkey CE-ESI-HRMS Workflow, Presented by Milla N., 908 Devices, Inc.

A04: Raman-Based Monitoring of Lactate Enables Lactate Feeding Strategy - Impact on Culture Characteristics and Product Quality in Mammalian Cell Cultures, Presented by Garrett S., 908 Devices, Inc.

A05: Mass Spectrometry Characterization of Adeno-Associated Virus 9 (AAV9), Presented by Alireza B., AbbVie Bioresearch Center, Inc.

A06: Effective CMC Due Diligence for Cell and Gene Therapy Products and Technology, Presented by Scott B., Advanced Cell & Gene Therapy, LLC

A07: Knowing the End of the Story While Writing the Beginning: Development of an Effective and Durable Cell/Gene Therapy CMC, Presented by William J., WEJ Cell & Gene Therapy Consulting Services, LLC

A08: Development of an Improved Upstream Process to Accelerate Multi-Modality Drug Discovery Pipeline, Presented by Keshab R., Amgen, Inc.

A09: High-Throughput Automated IVT with Liquid Handler, Presented by Brett H., Arcturus Therapeutics

A10: Standardizing Cell-Based Assays for Multiple TCR-T Cell Therapy Programs to Ensure Consistency and Reproducibility, Presented by Boning Z., TScan Therapeutics

A13: A Comparative Study to Evaluate Different Analytical Methods Used to Quantify a Fusion Protein and Two Types of IgG Molecules Produced in CHO Cell Line, Presented by Nida Z., Boston Institute of Biotechnology

A14: Unraveling Differences in Antibody Production Between Manufacturing Sites Using Omics Analysis, Presented by Tomoko W., Chugai Pharmaceutical Co., Ltd.

A15: Analytical Methods to Assess Critical Quality Attribute in mRNA-LNP Modality, Presented by Ye G., Crystal Pharmatech

A16: An Optimized and Validated Workflow for Developing Stable Producer Cell Lines with >99.99% Assurance of Clonality and High Clone Recovery, Presented by Sayak B., CYTENA GmbH

A17: Design and Production of Circular RNAs (circRNAs) with Validated Functional Activity in Cell Models., Presented by Patrick M., ElevateBio

A18: Bioprocess Intensification with Peptide-Based Cell Culture Media Optimization Using Tyrosine and/or Cystine (Di)Peptides, Presented by Zachary D., Evonik Corporation

A19: Quantitation of Replication Competent Lentiviruses (RCL) using ddPCR, Presented by Jim S., Frontage Labs Inc

A20: End-To-End Software Platform for Streamlined LC/MS-Based Multi-Attribute Method (MAM) Implementation, Presented by Aude T., Genedata AG

A21: A Plastic Micro-Fluidic Chip and System for Scalable Synthesizing Liposome, Presented by Yeong-Eun Y., Korea Institute of Machinery and Materials

A22: TheraPRO® CHO Media System: Achieve High Productivity in CHOK1 GS-KO® Cell Lines with Our Advanced Formulated, Easy-to-Use Media and Feed Solution, Presented by Lingqi K., Lonza

A23: A Production-Adapted, Multi-Auxotrophic, Cho Cell Line for Reducing Monoclonal and Bispecific Antibody Cell Line Development Timelines, Presented by James R., MilliporeSigma

A24: Characterization of Adeno-Associated Viral Vectors by SEC coupled with Light Scattering and UV Detection, Presented by Melin K., MilliporeSigma

A25: Optimizing Virus Filtration in Continuous Processing with Asymmetric Serial Filtration at High Membrane Area Ratio, Presented by Matthew T., MilliporeSigma

A26: Unlocking the High-Seed Fed-Batch Approach with Cellvento® ModiFeed Prime, Presented by Hariz H., Milliporesigma

A27: Benchtop High Resolution ES-DMA System Reveals Angstrom-Scale Size / Mass Correlation of Adeno-Associated Virus (AAV) Vectors for Gene Therapy Capsid Analytics, Presented by Bob D., NanoEngineering Corporation

A28: A New Method to Produce Genome-Free-HSV Particle Vector, Presented by Masato M., National Institute of Advanced Industrial Science and Technology

A29: Overcoming Challenges in Ferritin Extraction from Blood Plasma: Precise Affinity Chromatography Solutions, Presented by Josephine H., Navigo Proteins GmbH

A30: Analysis of the Oxidation Status of the N-Glycan Species in a Humanized Monoclonal Antibody by QTOF Mass Spectrometry, Presented by Jackson U., Nitto Avecia Pharma Services

A31: A T7 RNA Polymerase Mutant that Can Significantly Reduce dsRNA Impurities, Presented by Fei W., Novoprotein Scientific, Inc.

A32: Untargeted Metabolomic Profiling Reveals Process Optimization Strategies in a Mock Bioreactor, Presented by Tiffany B., Panome Bio

A33: Fractionation of Bispecific Antibody Charge Variants by MauriceFlex™ and their Identification by Mass Spectrometry, Presented by Peter J., ProteinSimple, A Bio-Techne Brand

A34: Behind the Scenes: Creation of a Broadly Reactive E. coli HCP Detection ELISA Suitable for K-Strain and B-Strain Platforms, Presented by Dan K., Rockland Immunochemicals, Inc.

A35: Selective Generation of mAb Degradants via Guided Modulation of Low pH Stress Conditions, Presented by Dennis D., Sanofi

A36: Targeted Dual Selection to Optimize Transposon Stable Pool Generation of Multi-Specifics in Large Molecules Research, Presented by Sonja T., Sanofi

A37: Monolithic Columns Enable Streamlined Downstream Processing and Analytics of Lipid Nanoparticles, Presented by Nejc P., Sartorius BIA Separations

A38: De-Bottlenecking the UF/DF Steps: Enhancing Recovery and Efficiency in a Continuous Downstream Process, Presented by Prateek J., Sartorius Stedim Biotech GmbH

A39: Charge Variant Identification and Localization of Post-Translational Modifications with Integrated icIEF-UV/MS, Presented by Steven C., SCIEX

A40: Differential Scanning Fluorimetry for Assessing Thermal Stability of Protein Biologics, Presented by Omair N., SGS Canada

A41: Hydrogels Mimicking T, B, and NK Cells for Quality Assurance in Cell Therapy Development, Presented by Sarah K., Slingshot Biosciences

A42: Enhancing Immunophenotyping Standardization with Quantitative BCMA or CD19 Decorated Hydrogels, Presented by Martina D., Slingshot Biosciences

A43: Evaluating a Platform Approach to Robust HCP and Viral Clearance Using a Novel Single-Use AEX Technology, Presented by Stephanie S., Solventum

A44: An Investigative Case Study of the Removal of Host Cell DNA from HEK Detergent Lysates using 3M™ Harvest RC Chromatographic Clarifier, Presented by Morgan L., Solventum

A45: Picodroplets for Biologics Discovery and Cell Line Development: Accelerating the Discovery and Development Process, Presented by Simona P., Sphere Fluidics Ltd.

A46: Customization of Gibco™ CHO Panel Formulations Produced by Gibco™ Rapid Prototyping™ Facility (GRP) Lead to Increase in Productivity for Two CHO Cell Lines with CHO-K1 and DG44 Lineages, Presented by Samantha K., Thermo Fisher Scientific

A47: Enhancing Protein Titer in CHO Cells with a Novel Protein-Free Two-Part Feed System, Presented by Amanda B., Thermo Fisher Scientific

A48: Improvement in Upstream Viral Vaccine Production Process Using Peptones, Presented by Matt R., Thermo Fisher Scientific

A49: Novel Pseudo-Affinity Reagents for Lentivirus Analytics and Affinity Chromatography, Presented by Brian B., Tozaro Ltd.

A50: Characterizing the mRNA Expression Profile Associated with Accelerated Aging for the Development of Anti-Aging Biotherapeutics, Presented by Oscar C., University Jaume I

A51: Host Characteristics and Changes in Omics Biomarkers Following Vaccination with Distinct COVID-19 Vaccines in an Elderly Mediterranean Population, Presented by Dolores C., University of Valencia

A52: Simple and Rapid Analytics for Protein Titer & Aggregation Quantification, Presented by Chip S., ValitaCell Ltd., now part of Beckman Coulter Life Sciences

A53: Advances in Downstream PAT for Biologics, Vaccines and Gene Vectors, Presented by Daniel S., Wyatt Technology Corporation

A54: Extended Cycle Lifetime Study of Fibro PrismA Rapid Cycling Chromatography Using Cytiva’s HiTrap and HiScreen Devices, Presented by Donglee S., Zoetis

A55: Process Intensification with Single Use Technologies and the Impact on Economic and Sustainability Metrics, Presented by Nikki S., Solventum

A56: Streamlined Protein Quality Assessment with Revvity’s High Throughput Biotherapeutics Workflow Solutions, Presented by Menel BF., Revvity

B01: Osmolality Testing of Viscous Formulations Using Freezing Point Depression, Presented by Isaac M., Advanced Instruments, Inc.

B02: Enhancing Platform Process Using Membrane Chromatography (Affinity/Protein-A, Using Sartobind Rapid A) for FIH Molecules with Focus on Optimizing Cost and Accelerating Timelines, Presented by Indraneel S., Aragen Biologics Private Limited

B03: Evolving Challenges of Achieving Scalable and High Recovery rAAV Production, Presented by Greg S., Avantor, Inc.

B04: Enhanced CAR-T Transduction with Lentiviral Vector (LV) in Medium Supplemented with Poloxamers P 188 and P 338, Presented by Philip B., BASF Corporation

B05: Evaluation of Foam Stability and Shear Protection of Kolliphor® P188 Bio and Kolliphor® P188 Cell Culture, Presented by Tamara V., BASF Corporation

B06: Impact of Poloxamer 188 on Membrane Rigidity and Lipid Content of CHO-S cells, Presented by Jack S., BASF Corporation

B07: Investigating Poloxamer 188 and Cell Membrane Interaction in CHO-S Cells Using Microscopy, Presented by David R., BASF Corporation

B08: Multifaceted Application of the Cue Cell Processing System for Automated and Closed Manufacturing of CD34+ Hematopoietic Stem and Progenitor Cells (HSPCs), Presented by Margaret Z., Beam Therapeutics

B09: An Assessment of Eco-Friendly Surfactants as Replacements for Triton™ X-100 During Cell Lysis, and Their Impact on the Primary Capture of a Therapeutic Protein, Presented by Salvador VR., Boston Institute of Biotechnology

B10: Effective Log Reduction of RVLP as Proof of Concept for Viral Clearance on BioRMB™ - A Column-Free and Continuous Purification Platform for Gene Therapies, Vaccines, and Biologics, Presented by Dalton K., Chromatan, Inc.

B11: How to Compare the Technical Performance of S. marcescens endonucleases such as DENARASE® & Benzonase®?, Presented by Raphael G., c-LEcta GmbH

B12: High-Efficiency DNA Removal from No to High Salt. DENARASE® High Salt – Engineered Innovation, Presented by Timothy M., c-LEcta GmbH

B13: Rapid Development of Ion Exchange Chromatography for Full/Empty Separation in Adeno-Associated Virus Serotype 5, Presented by Jay C., ElevateBio

B14: Evaluation of Alternative Process Cell Lysis Reagents as Replacements for Triton™ X-100 for AAV Production, Presented by Theresa D., ElevateBio

B15: Enhancing a Technique for Polishing Bispecific Antibodies Using Ion-Exchange Chromatography, Presented by Stefan S., Evitria AG

B16: Adaptive Downstream Platform Process for Accelerated rAAV Therapeutic Development: Integrating Serotype-Specific Optimization, Presented by Keerthana S., Forge Biologics

B17: Patient-Derived Tumor Spheroid-Induced Angiogenesis Preclinical Platform, Presented by Won-Suk L., Gachon University

B18: Automated and Robust Identification of Scrambled Disulfide Bonds in Biotherapeutics, Presented by Yaarub M., Genedata AG

B19: Introduction to Genevoyager's One-Bac 4.0 System: Addressing the Bottlenecks and Challenges of Adeno-Associated Virus (AAV) Manufacturing, Presented by Hui W., Genevoyager, Inc.

B20: Enabling Intravenous Co-Administration of Two Monoclonal Antibodies Enhancing Patient Convenience, Presented by McKenzie B., Gilead Sciences

B21: Building a Fully Single-Use Process: High Productivity Protein A Membrane Devices that Complement Disposable Upstream Technology, Presented by Jeffrey C., W. L. Gore & Associates, Inc.

B22: High-Throughput, Automated Analysis of Process Related Impurities Accelerates Downstream Process Development of AAV Based Gene Therapies, Presented by Maria G., Gyros Protein Technologies

B23: AI-Enhanced Biotechnology Solutions for Early Synergistic Intervention in Cerebral Palsy, Presented by Alim O., Harvard Medical School

B24: The Design and Manufacture of Massively Scalable Inertial Focusing Prototype Microfluidic Devices, Presented by Tom C., Heriot-Watt University

B25: Salt Addition Impacts Recombinant AAV Particle Distribution in Cell Culture, Presented by Nicholas S., Intellia Therapeutics, Inc.

B26: Cryoprotectant Additives Including rHSA Improve iNK and iT Cell Health and Viability During Cryopreservation, Presented by Elliott R., InVitria

B27: IsoTags - Novel and Effective Tools in Biotherapeutic Purification Arsenal, Presented by Saurabh M., Isolere Bio

B28: RT-MALS Assisted Purification of Adeno-Associated Viruses During Early Process Development, Presented by Michael H., Lonza

B29: In Silico Tool: Integrated Downstream Processing Platform for Monoclonal Antibodies Production, Presented by Sofia N., Lonza

B30: Ministring DNA (msDNA™ ): Maximizing Quality of Novel DNA Vectors, Presented by Nafiseh N., Mediphage Bioceuticals, Inc.

B31: PAT for Flocculation Across Scales, Presented by Jennifer S., Merck & Co., Inc.

B32: Evaluation of a High Throughput Scale Down Model for UFDF Operation, Presented by Akaash M., Merck & Co., Inc.

B33: Development of a Dissolved CO2 Sensor in True Single-Use Format, Presented by Stefan B., Mettler Toledo GmbH

B34: Development of a Novel Cell Culture Medium and Process Optimization for AAV Production in Multiple HEK293 Lineages, Presented by Jessica H., MilliporeSigma

B35: EndoS2 followed by LC-MS/MS Analysis to Verify Knock Out of FUT8 in CHO Cells, Presented by Felicia R., MilliporeSigma

B36: High-Throughput Activity Assay for Prime Editor mRNA, Presented by Amanda J., Prime Medicine, Inc.

B37: Viral-Vector Therapies at Manufacturing Scale: Current Challenges and Future Opportunities, Presented by Rachel L., Repligen Corporation

B38: Addressing the HEK293 Host Cell Protein Monitoring Challenges for Viral Vector Gene Therapy Manufacturing, Presented by Olivia K., Revvity, Inc.

B39: Anti-Bubble OptoCap Technology in In-Line Dissolved Oxygen Sensors Can Increase Measurement Precision for Fermenter Applications, Presented by Ehsan M., Mettler Toledo GmbH

B40: Enhancing rAAV Genome Integrity Through Process Development Optimization, Presented by Tomas AF., Sarepta Therapeutics

B41: Fiber Chromatographic Clarification: Enhancing Rapid Cycling Protein A Chromatography Performance, Presented by Andrew V., Solventum

B42: A Case Study for Understanding Impact of Nuclease Elimination on Bioprocess Cost and Downstream AAV5 Quality Using 3M™ Harvest RC Chromatographic Clarifier, Presented by Mauhamad B., Solventum

B43: Scalable Upstream Design: Robustness and Reproduceable Suspension Production from Benchtop to 500L STR Scale, Presented by Huize Y., Spark Therapeutics

B44: The Optimization of Nuclease Application in AAV-Based Gene Therapy Manufacturing, Presented by Yixuan M., Spark Therapeutics

B45: Monitoring Polysorbate 80 Degradation as a Function of pH using Total Holographic Characterization, Presented by Laura P., Spheryx, Inc.

B46: Exceptional High Alkaline Stability Combined with High Dynamic Binding Capacity for Scalable and Cost-Effective mAb Purification with New rProtein A Agarose Resin, Presented by Simona S., Sunresin New Materials Co., Ltd.

B47: A Unified View of Virus and Recombinant Protein Interactions with Block Copolymer Membranes, Presented by Markus M., TeraPore

B48: Impacts of Amino Acids in Formulation on Imaged Capillary Isoelectric Focusing (icIEF), Presented by Nicole P., Teva Pharmaceuticals

B49: Accelerating Antibody Drug Development with Subdomain-Specific Affinity Chromatography, Presented by Eugene S., Thermo Fisher Scientific

B50: Moving Forward: Rapid Detection of Bacteria and Fungi in Cell Therapy Products, Presented by Min L., Thermo Fisher Scientific

B51: An Accelerated Approach to Upstream Process Characterization of an AAV-Based Gene Therapy for Sanfilippo Syndrome (MPSIIIA), Presented by Connor S., Ultragenyx Pharmaceutical, Inc.

B52: Development of a High Throughput Purification Method to Support Late-Stage Development and Process Characterization of an Accelerated Clinical Program, Presented by Mike D., Ultragenyx Pharmaceutical, Inc.

B53: Unlocking Optimal Conditions for HEK293T Cell Expansion Using SCINUS Bioreactor Technology, Presented by Javier OB., University of Groningen

B54: AttIL12-T Cell Therapy Destructs Cancer-Associated Fibroblasts and Extracellular Matrix in Heterogenous Osteosarcoma Xenograft Models, Presented by Xueqing X., University of Texas MD Anderson Cancer Center

B55: Development of an Ion Exchange Purification Process for Lentiviral Vectors, Presented by Erik V., Bio-Rad Laboratories

B56: Implementing Sustainability in mAb Purification Workflows, Presented by Renee S., Bio-Rad Laboratories

B57: Separation of Bispecific-Antibody Related Impurities with Mixed-Mode Chromatography, Presented by William R., Bio-Rad Laboratories